November 27, 2024
About 40% of American adults — some 137 million — are eligible to take the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide, said authors of a […]
November 27, 2024
Disparate views on managing incidental imaging findings made during clinical research — particularly for unclear results — signal a need for standardized guidance, according to recent […]
November 27, 2024
Long COVID is a symptom-driven disease, meaning that with no cure, physicians primarily treat the symptoms their patients are experiencing. Effective treatments for long COVID remain […]
November 27, 2024
TOPLINE: In children with traumatic hemorrhage, tourniquets placed before the arrival of emergency medical services (EMSs) are associated with decreased initial acuity, and all providers, including […]
November 27, 2024
Within days of Donald Trump’s election victory, healthcare entrepreneur Calley Means turned to social media to crowdsource advice. “First 100 days,” said Means, a former consultant […]
November 27, 2024
“For too long, the management of psoriasis and other immune-mediated inflammatory diseases has suffered from an acceptance that improvement rather than cure is good enough. Our […]
November 27, 2024
TOPLINE: Insurance loss more than 2 months after childbirth is associated with 26% lower odds of prescription contraception use, with Hispanic Spanish-language respondents experiencing higher rates […]
November 27, 2024
About a third of people eligible for glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications for weight loss via the products’ labels would have been excluded […]
November 27, 2024
TOPLINE: Detection rates for ketamine in drug overdose deaths in the United States increased from 0.3% in 2019 to 0.5% in 2023, a new study shows. […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487
Next page